PD-1 inhibitors
Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
... with PD-1 ...criteria: 1) prospective RCTs evaluating patients with solid tumors, 2) patients were allocated to treatment with PD-1 inhibitors (nivolumab 3 mg/kg, pembrolizumab 2 ...
9
Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors
... with PD-1 inhibitors for cancer were subjected to immunohistochemical and ultrastructural analyses to localize CD8+ cytotoxic cells and markers of lymphoid ...
7
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
... Discussion: Histologic transformation from NSCLC to SCLC can be explained by the pres- ence of a common cell precursor. Proposed molecular mechanisms include loss of RB1, TP53 mutations, and MYC amplification. The ...
6
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
... Pixatimod inhibits the infiltration of tumor-associated macrophages (TAMs) [9, 10] but, moreover, it also stimu- lates dendritic cells (DCs) [11]. In terms of its immuno- modulatory activity on TAMs, there is preclinical ...
13
Review Article The progress of PD-1 inhibitors in small-cell lung cancer
... of PD-1 and CTLA-4 have shown its promising antitumor activity, especially when tumor recombinant vaccinations ...in PD-1 inhibitors, nivolumab and pem- brolizumab treatment, compared ...
11
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
... checkpoint inhibitors are becoming widely used in multiple tumor types, they are also being used in B cell ...of PD-1 inhibitors in patients with underlying autoimmune disorders treated with B ...
7
<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>
... CTLA-4 inhibitors have a signifi- cantly higher risk of FAE (P = ...whereas PD-1 inhibitors were ...common PD-1-related FAE was pulmonary ...
10
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
... Checkpoint inhibitors are revolutionizing treatment options and expectations for patients with ...death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and ...
14
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
... death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration resistant prostate cancer (mCRPC) showed no evidence of ...
8
Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy
... checkpoint inhibitors across multiple oncologic disorders have systematically excluded patients with advanced organ failure and/or active viral infections that could derive in unpredictable immune alterations ...
5
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
... different PD-1 and PD-L1 inhibitors in several solid tumor and hematological malignancies as of May 2017, it is anticipated that clinical decisions facing patients and physicians as described ...
5
<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>
... assessed PD-L1 inhibitors (atezolizumab = 5, durvalumab = 3, and avelumab = 1), and five trials assessed PD-1 inhibitors (pembrolizumab = 3 and nivolumab = ...
11
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
... The results of this study also pose further scientific questions. Significantly, the mechanism by which dynamic changes in NLR were correlated with improved prognosis was not explained purely by an increase in the ...
23
Review Article Therapeutic effects and associated adverse events of PD-1 and CTLA-4 pathway inhibitors in the treatment of non-small-cell lung cancer: meta-analyses of clinical phase II/III randomized controlled trials
... CTLA-4 inhibitors on NSCLC is still limited. Further, although the PD-1 and PD-L1 inhibitors, such as Nivolumab [20, 21], Pembrolizumab [22], and Atezolizumab [23], exhibited ...
10
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
... resistance, PD-L1 expression threshold, more sensitive biomarker assays, immune-related toxicity, and treatment duration are ...checkpoint inhibitors, other immunotherapy tar- geting cytokines, ...
13
Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
... An advantage of our study was the ability to assess out- comes in smokers versus nonsmokers in a larger sample size as opposed to data often obtained from comparatively small group in RCTs. Nevertheless, this ...
6
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
... In a recent meta-analysis of patients with immune-me- diated inflammatory diseases treated with anti-TNF (tumor necrosis factor), the authors reported a trend towards a lower response rate to treatment among over- weight ...
11
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
... Serial 4 µm formalin-fixed paraffin-embedded tissue sec- tions from ESCC were stained for IHC analysis. Deparaf- finization was carried out with xylene, and the sections were subsequently hydrated with an ethanol ...
12
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
... Establishment of the human PBMC-engrafted mouse model This study was approved by the Institutional Review Board of Peking University People’s Hospital. Blood samples were collected from donors with written informed ...
13
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
... CARs, which consisted of only an HLA-independent extracellular domain and an intracellular T cell acti- vating domain comprised of the zeta chain of the CD3 complex, exhibited limited efficacy due to their inability to ...
6